D&D Pharmatech tumbles 18% after Pfizer halts ORALINK candidate [K-bio pulse]
D&D Pharmatech shares fell 18.06% to 53,100 won on Aug. 5 after Pfizer discontinued development of MET-224o, an obesity candidate using D&D Pharmatech’s ORALINK oral peptide platform, according to Pfizer’s Q2 materials. D&D Pharmatech said the halt is strategic and not a technical ORALINK issue.
How this was made
![D&D Pharmatech tumbles 18% after Pfizer halts ORALINK candidate [K-bio pulse] — source image](/_next/image?url=%2Fdata%2Fnews-image%3Furl%3Dhttps%253A%252F%252Fimage.edaily.co.kr%252Fimages%252FPhoto%252Ffiles%252FNP%252FS%252F2026%252F08%252FPS26080700705.820x.0.jpg&w=3840&q=75)
The 30-second read
Why it matters
Pfizer's discontinuation of MET-224o is the immediate negative catalyst driving D&D Pharmatech's sharp selloff, while D&D Pharmatech counters that the issue is strategic rather than technical. The market reaction is amplified by earlier obesity-platform skepticism in Korea.
Market read
A specific obesity pipeline cut (MET-224o) linked to ORALINK triggers a sharp repricing of platform risk, even as Pfizer and D&D Pharmatech frame it as strategic rather than technical.
What to watch
The article notes Pfizer will continue pursuing oral peptide GLP-1s and multi-agonists; remaining ORALINK-linked candidates (MET-097o) could limit long-term damage if they progress.
Background
The article ties D&D Pharmatech's ORALINK platform to Pfizer's obesity program via MET-224o, and contrasts this with prior market controversy around Peptron's Lilly technology evaluation agreement.
Ticker impact
Pfizer discontinued development of MET-224o, an obesity candidate built on D&D Pharmatech's ORALINK platform, per its Q2 materials.
Likely limited direct impact versus broader obesity franchise, but can pressure sentiment around oral peptide strategy.
The article frames the halt as a strategy shift, yet it is a concrete pipeline cut tied to a specific candidate (MET-224o).
Market effects
Oral peptide GLP-1 platform risk premium may rise as investors reassess how quickly partners can cut programs after acquisitions or strategy shifts.
Korean biotech obesity names may see correlated volatility tied to partner pipeline decisions.
Signals competitive pressure in obesity drug development and potential reprioritization away from certain oral peptide approaches at large pharma.
Counterpoint
Management argues ORALINK is not broken and that Pfizer is discontinuing one product after early-trial visibility, implying platform risk may be overstated.
Key entities
- companyD&D Pharmatech
ORALINK oral peptide platform provider whose shares fell 18% after Pfizer halted MET-224o development.
- companyPfizer
Discontinued development of MET-224o in its Q2 materials, citing strategy change.
- companyMetsera
Acquired by Pfizer; previously developed MET-224o using ORALINK under a 2023 licensing deal.
- drug_candidateMET-224o
Oral GLP-1 receptor agonist candidate built on ORALINK that Pfizer discontinued.
- technology_platformORALINK
D&D Pharmatech's oral peptide platform used in MET-224o.
